为患有非阻塞性冠状动脉心肌梗塞的患者提供个性化的方法
Leonardo De Luca1, Federico Andreoli1, Raffaella Mistrulli1
1Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini, 00152 Rome, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
不阻塞冠状动脉的心肌梗塞 (MINOCA) 影响6-8%的急性心肌梗塞 (AMI) 患者. 识别MINOCA的原因对于个性化治疗和预防复发性心脏病发作至关重要.
科学领域:
- 心脏病学 心脏病学
- 心血管医学 心血管医学
背景情况:
- 不阻塞冠状动脉的心肌梗塞 (MINOCA) 占急性心肌梗塞 (AMI) 病例的6-8%.
- MINOCA涵盖了各种疾病,包括栓塞,解剖,,微血管功能障碍和非阻塞性斑块破裂/侵蚀.
- MINOCA的预后与其他AMI类型相似,需要准确的诊断和量身定制的管理.
研究的目的:
- 为了回顾MINOCA的各种原因.
- 讨论每个MINOCA病因的具体疗法.
- 倡导为MINOCA患者提供个性化的治疗方法.
主要方法:
- 这项研究是对MINOCA现有文献的叙述性综述.
- 它综合了冠状动脉血管学以外的诊断程序的信息,包括心脏成像和挑性测试.
- 重点是心磁共振 (CMR) 在诊断和差异诊断中的作用.
主要成果:
- MINOCA包括一系列的病因,不仅仅是阻塞性冠状动脉疾病.
- 心脏磁共振 (CMR) 对于确认MINOCA和排除模仿者至关重要.
- 目前的指导方针建议确定潜在原因,以优化治疗和预防.
结论:
- 准确诊断MINOCA的根本原因对于有效管理至关重要.
- 个性化治疗策略可以改善结果并预防复发事件.
- 对MINOCA病因和治疗方法的进一步研究是有必要的.
更多相关视频
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
24.2K
10:01Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
10.8K
相关概念视频
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
